Search | Clinical Trials Finder

Conditions: Multiple Myeloma
Interventions: Pembrolizumab, Daratumumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Jacksonville, Florida • Atlanta, Georgia • Bloomfield Hills, Michigan

Conditions: Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions: rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan; Drug · Procedure · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: DS-8273a, Nivolumab; Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions: Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Monterey, California • Orange, California + 19 more

Conditions: Advanced Solid Tumors Cancer
Interventions: Livmoniplimab, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 21
States / cities: Springdale, Arkansas • Duarte, California • Irvine, California + 16 more

Conditions: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Interventions: Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP); Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 30
States / cities: Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more

Conditions: Esophageal Neoplasms
Interventions: Pembrolizumab, Placebo, Cisplatin, 5-FU; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 749 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 12
States / cities: West Los Angeles, California • Chicago, Illinois • Westwood, Kansas + 9 more

Conditions: Obesity
Interventions: Portion controlled diet, Diabetes Support and Education; Behavioral · Other
Lead sponsor: Temple University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: The Woodlands, Texas

Conditions: Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis, ILD, Normal Controls
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Adenocarcinoma of the Prostate
Interventions: Muscadine Plus, Placebos; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 13
States / cities: Duarte, California • La Jolla, California • Aurora, Colorado + 10 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 18
States / cities: Anchorage, Alaska • Chandler, Arizona • Bakersfield, California + 15 more

Conditions: Non-Alcoholic Steatohepatitis (NASH)
Interventions: SEL, SIM; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 21 more

Conditions: Neoplasm Metastasis
Interventions: PF-07265807, Sasanlimab, Axitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more

Conditions: Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
Interventions: Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Pembrolizumab, Autologous Tumor Infiltrating Lymphocytes LN-145, Aldesleukin; Drug · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Parkinson Disease
Interventions: Protein Redistribution Diet, Protein Consistent Diet; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 45 Years to 99 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Primary Ciliary Dyskinesia
Interventions: nNO testing; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 1 Year and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV-1 Seropositive, Inflammation, Cancer, Cardiomyopathy
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Advanced Solid Tumors
Interventions: ARRY-382, Pembrolizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 30
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 12 more

Conditions: Neoplasms
Interventions: Veliparib + VX-970 + Cisplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Bethesda, Maryland • Boston, Massachusetts • Houston, Texas

Conditions: Renal Cell Carcinoma, Kidney Cancer
Interventions: Durvalumab, Tremelimumab; Drug
Lead sponsor: Moshe Ornstein; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Cleveland, Ohio

Conditions: Bronchiectasis, Cystic Fibrosis, Autoimmune Disease, Common Variable Immunodeficiency
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 5 Years to 100 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: Not listed
Lead sponsor: Pierian Biosciences; Industry
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 10
States / cities: La Verne, California • Tampa, Florida • Brentwood, Tennessee + 3 more

Conditions: Colorectal Cancer
Interventions: favezelimab/pembrolizumab, regorafenib, TAS-102; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more

Search by objective public record fields.

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

The Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control: A Comparison Study

A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

High Resolution Micro OCT Imaging

Muscadine Plus (MPX) In Men With Prostate Cancer

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Optimizing Protein Patterns for Skeletal Muscle Preservation and Sleep in the Medical Management of Parkinson Disease

Utility of PCD Diagnostics to Improve Clinical Care

Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Natural History of Bronchiectasis

Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)